Communiqués AbbVie Inc. BOERSE MUENCHEN

Actions

4AB

US00287Y1091

Marché Fermé - BOERSE MUENCHEN Autres places de cotation 21:57:15 27/06/2024			Varia. 5j.	Varia. 1 janv.
158 ^EUR	-1,92 %		+1,33 %	+15,33 %

27/06	Mise à jour sectorielle : Les actions du secteur de la santé en baisse en fin d'après-midi	MT
27/06	Mise à jour sectorielle : Les actions du secteur de la santé en baisse dans l'après-midi	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

AbbVie Acquires Celsius Therapeutics	27/06	PR
AbbVie - U.S. Food and Drug Administration Grants Second Approval for EPKINLY to Treat Patients with Relapsed or Refractory Follicular Lymphoma	27/06	AQ
Introducing Allē Payment Plans, Powered by Cherry	27/06	PR
U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma	27/06	PR
AbbVie Provides U.S. Regulatory Update on ABBV-951	26/06	AQ
AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)	25/06	PR
AbbVie Declares Quarterly Dividend	24/06	AQ
AbbVie Declares Quarterly Dividend	21/06	PR
AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors	20/06	PR
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease	19/06	PR
AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer	14/06	PR
AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease	13/06	PR
BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant Recipients	11/06	PR
AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers	07/06	AQ
AbbVie - SkinMedica Celebrates 25 Years of Empowering Radiant Skin	07/06	AQ
AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer	06/06	PR
SkinMedica® Celebrates 25 Years of Empowering Radiant Skin	06/06	PR
AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383	05/06	PR
RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis	04/06	PR
Refer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50	04/06	PR

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués AbbVie Inc. BOERSE MUENCHEN

Actions

4AB

US00287Y1091

Communiqués

Filtres